Free Trial
NASDAQ:VCNX

Vaccinex (VCNX) Stock Price, News & Analysis

Vaccinex logo
$1.00 +0.24 (+31.41%)
As of 04/1/2025 03:59 PM Eastern

About Vaccinex Stock (NASDAQ:VCNX)

Key Stats

Today's Range
$0.68
$1.00
50-Day Range
$0.55
$1.29
52-Week Range
$0.28
$8.90
Volume
2,390 shs
Average Volume
57,184 shs
Market Capitalization
$2.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.

Remove Ads
Receive VCNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaccinex and its competitors with MarketBeat's FREE daily newsletter.

VCNX Stock News Headlines

Vaccinex director resigns, no disagreement cited
DOGE tax surprise
Elon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax authorities have bought a powerful new AI supercomputer, worth millions of dollars. It's the most advanced technology offered by AI giant Nvidia. And it's almost certainly going to be used to advance Elon Musk's real agenda with DOGE... the massive, rapid roll out of AI across the entire federal government.
Vaccinex to delist common stock from Nasdaq
Vaccinex receives delisting notification from Nasdaq
Vaccinex Announces Receipt of Delisting Notification from Nasdaq
See More Headlines

VCNX Stock Analysis - Frequently Asked Questions

Vaccinex's stock was trading at $0.98 on January 1st, 2025. Since then, VCNX shares have increased by 2.0% and is now trading at $1.00.
View the best growth stocks for 2025 here
.

Vaccinex, Inc. (NASDAQ:VCNX) posted its quarterly earnings data on Monday, November, 8th. The company reported ($35.70) earnings per share for the quarter, beating the consensus estimate of ($60.90) by $25.20. The company earned $0.05 million during the quarter.

Vaccinex shares reverse split on the morning of Tuesday, February 20th 2024. The 1-14 reverse split was announced on Tuesday, February 20th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Vaccinex (VCNX) raised $45 million in an initial public offering (IPO) on Thursday, August 9th 2018. The company issued 3,300,000 shares at a price of $12.00-$15.00 per share. Oppenheimer and BTIG served as the underwriters for the IPO and Ladenburg Thalmann was co-manager.

Shares of VCNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vaccinex investors own include Pfizer (PFE), VBI Vaccines (VBIV), OPKO Health (OPK), Plug Power (PLUG), Vaxart (VXRT), NIO (NIO) and SNDL (SNDL).

Company Calendar

Last Earnings
11/08/2021
Today
4/02/2025
Next Earnings (Estimated)
5/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VCNX
Employees
40
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-20,250,000.00
Pretax Margin
-4,787.89%

Debt

Sales & Book Value

Annual Sales
$388,000.00
Price / Cash Flow
N/A
Book Value
($2.59) per share
Price / Book
-0.39

Miscellaneous

Free Float
1,261,000
Market Cap
$2.60 million
Optionable
No Data
Beta
1.10
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:VCNX) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners